{"id":"ak112-low-dose","_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T03:20:32.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123495,"model":"claude-sonnet-4-5-20250929"},"description":"AK112 low dose is an investigational bispecific antibody being developed by Akeso for cancer treatment. It is currently in Phase 2 clinical trials. The drug represents a novel immunotherapy approach, though specific molecular targets and approved indications have not yet been established.","indications":{"approved":[{"status":"investigational","condition":"Cancer (specific type unknown)","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT07162714","phase":"PHASE2","title":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-09-01","conditions":"Rectal Cancer, Radiation, AK112","enrollment":30},{"nctId":"NCT06686030","phase":"PHASE2","title":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-17","conditions":"Platinum-sensitive Ovarian Cancer","enrollment":150},{"nctId":"NCT06791148","phase":"PHASE2","title":"Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-07-10","conditions":"Gastric Cancer","enrollment":45},{"nctId":"NCT06593548","phase":"PHASE2","title":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-01","conditions":"CRC, MSS, Metastatic Cancer","enrollment":36},{"nctId":"NCT04999605","phase":"PHASE1, PHASE2","title":"A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Akeso","startDate":"2021-06-24","conditions":"Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ivonescimab"],"phase":"phase_2","status":"active","brandName":"AK112 low dose","genericName":"AK112 low dose","companyName":"Akeso","companyId":"akeso","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}